Besides David Nance, Max Talbott and Robert Sobol, other clinicians not directly connected with INGN, participated in the CC including:
Dr. Jack Roth, inventor of ADVEXIN and professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic & Cardiovascular Surgery, Section Chief, Thoracic Molecular Oncology, and Director, W.M. Keck Cancer Center for Innovative Cancer Therapies, M.D. Anderson Cancer Center, Houston, TX.
Dr. John Nemunaitis, a principal investigator of Introgen’s phase III study and medical director, Mary Crowley Cancer Research Center at Baylor-Charles A. Sammons Cancer Center, Dallas, TX.
Dr. John Hamm, Medical Director, Louisville Oncology at Norton Healthcare, Louisville, KY.
and Dr. Jarrard Goodwin, Director, Sylvester Comprehensive Cancer Center/University of Miami Hospital and Clinics and Sylvester Professor, Department of Otolaryngology-Head and Neck Surgery.
All of the participants expressed favorable opinions on Advexin; Dr. Hamm mentioned one patient he treated wich showed remarkably positive tumor response and was alive one year after treatment.
Of course, I am aware of the existing bias against gene therapy , and the long campaign against INGN by the shorts.
At last count, although the short position has come down some, still was about 16x the AvgDaylVol or 12% of the float.The insiders reportedly hold 25% and funds 35% of the shares.
finance.yahoo.com
Dr John N Kapoor, the Chairman of Akorn,and Preident of EJ Financial Enterprises,reportedly was holding more than 3M shrs at the end of May.
finance.yahoo.com
The approval of Advexin is no doubt still a long shot, but if it gets approved for Head & Neck tumors, it will probably be used in other tumors with abnormal p53, like in prostate and breast.
In a series of prostate Cas, the expression of p53 was noted in 114 of 175 (65.1%) patients with a 5-year failure rate of 51.1%, compared with a 5-year failure rate of only 22% in p53 negative patients.
At any rate, the FDA will not consider INGN's application for Advexin until next Yr., so it is still too early to draw final conclusions.
I still don't mind keeping my position in INGN, since as previously mentioned,I figured that it has a negative cost.<g>
The consensus of the 1Yr. "target" for INGN, according to Yahoo is around $8.75. I would be more than satisfied if it can get back to $5 <g>
finance.yahoo.com
Bernard |
